AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS



Congenital abnormalities by the numbers

Congenital abnormalities are among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned by the American Academy of Dermatology. The report examined prevalence, economic burdens, and mortality for skin disease in the U.S. using 2013 health care claims data drawn from insurance enrollment and claims databases and found that:

- **84.5 million** Americans one in four saw a physician for skin disease; 50% of them are over 65 and have an average of 2.2 skin conditions.
- Skin disease cost the U.S. healthcare system \$75 billion in medical, preventative, and prescription and non-prescription drug costs.
- One in three Americans with skin disease were seen by a dermatologist, who collaborate with other physicians throughout the health care system in caring for these patients.

More than 961,000 Americans sought medical treatment in 2013 related to congenital abnormalities of the skin, a category that includes a number of diseases including hemangiomas, ichthyosis congenita, vascular hamartomas, and congenital ectodermal dysplasia. Congenital abnormalities:

- Were more prevalent in children than adults.
- Resulted in **\$205 million** in medical costs.
- Mean a potential decrease in lifespan of 20 years.


The charts that follow provide topline data on how congenital abnormalitis contribute to the overall burden of skin disease.

The full report includes data on prescription and non-prescription drug costs, and how age and insurance status and provider relate to the burden associated with congenital abnormalities and skin disease broadly. To purchase the report visit www.aad.org/BSD.

Prevalance

NUMBER OF CARED-FOR INDIVIDUALS


CONGENITAL ABNORMALITIES
OTHER SKIN DISEASES



^{*}This category is clinically broad in nature and includes, among other diseases: benign neoplasms, melanocytic nevi (unspecified), pilar cysts, pilonidal cysts (with or without abscess), scars and fibrosis, etc.

CONGENITAL ABNORMALITY PATIENTS BY AGE*

CONGENITAL ABNORMALITIES
OTHER SKIN DISEASES




^{*}Percentage of congenital aabnormality patients seen by a physician by age group.

Cost

TOTAL MEDICAL COST*


CONGENITAL ABNORMALITIES
OTHER SKIN DISEASES



^{*}In millions of dollars compared to most costly skin diseases.

COST OF SKIN DISEASE PER AFFECTED PERSON*

CONGENITAL ABNORMALITIES
OTHER SKIN DISEASES




^{*}Compared with most costly skin diseases.

^{**}This category is clinically broad in nature and includes, among other diseases: benign neoplasms, melanocytic nevi (unspecified), pilar cysts, pilonidal cysts (with or without abscess), scars and fibrosis, etc.

^{***} Represents combined data for melanoma and nonmelanoma skin cancer.


^{**} Represents combined data for melanoma and nonmelanoma skin cancer.

Life Impact



^{*}Provides the total number of deaths and average age at death from congenital abnormalities compared with other skin diseases with highest mortality.

YEARS OF POTENTIAL LIFE LOST*




^{*}Estimate/projected number of life years lost due to congenital abnormalities compared to top skin diseases leading to early death; Projected based on prototypical lifespan of 75 years.

^{**} Represents combined data for melanoma and nonmelanoma skin cancer.

Life Impact (cont'd)

LOST PRODUCTIVITY (OPPORTUNITY COST)*

CONGENITAL ABNORMALITIES
OTHER SKIN DISEASES



^{*}Time lost by patients and/or caregivers multiplied by average wages in 2013 (\$192/day); In millions of dollars compared with skin diseases leading to the most loss of productivity.

^{**}This category is clinically broad in nature and includes, among other diseases: benign neoplasms, melanocytic nevi (unspecified), pilar cysts, pilonidal cysts (with or without abscess), scars and fibrosis, etc.



Copyright © 2017 by American Academy of Dermatology. All rights reserved.

This information is intended for personal/noncommercial use and may not be reproduced in any form by any means (electronic, mechanical, or other) or held in any information storage and retrieval systems without written permission from the publisher.

Commercial use or distribution

For information on obtaining copies of this publication or to license the content for distribution, please visit www.aad.org/BSD for details and to complete an application.